公开(公告)号：US20240124468A1

公开(公告)日：2024-04-18

申请号：US18257746

申请日：2021-12-15

申请人： CHILDREN'S HOSPITAL MEDICAL CENTER ,  The United States of America, as Represented by the Secretary, Dept. of Health and Human Services ,  KUROME THERAPEUTICS, INC.

发明人： Scott Bryan HOYT ,  Craig Joseph THOMAS ,  Daniel T. STARCZYNOWSKI ,  Patrick Joseph SUTTER ,  Gregory James TAWA ,  Chris James FINOCCHIO ,  Jan Susan ROSENBAUM ,  Gabriel GRACIA MALDONADO

IPC分类号： C07D487/04 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/635 ,  A61P35/02 ,  C07D519/00

CPC分类号： C07D487/04 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/635 ,  A61P35/02 ,  C07D519/00

摘要： Some embodiments of the disclosure include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.), Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.

公开(公告)号：US20240294530A1

公开(公告)日：2024-09-05

申请号：US18258586

申请日：2021-12-23

申请人： CHILDREN'S HOSPITAL MEDICAL CENTER ,  THE UNITED STATES OF AMERICA,ASREPRESENTED BY THE SECRETARY,DEPT. OF HEALTH AND HUMAN SERVICES ,  KUROME THERAPEUTICS, INC.

发明人： Scott Bryan HOYT ,  Craig Joseph THOMAS ,  Daniel T. STARCZYNOWSKI ,  Jan ROSENBAUM ,  Gavriel GRACIA MALDONADO

IPC分类号： C07D487/04 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/541 ,  A61K31/635 ,  A61P35/02 ,  C07D519/00

CPC分类号： C07D487/04 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/541 ,  A61K31/635 ,  A61P35/02 ,  C07D519/00

摘要： Some embodiments of the disclosure include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.), Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.

公开(公告)号：US20230303563A1

公开(公告)日：2023-09-28

申请号：US18018742

申请日：2021-07-31

申请人： CHILDREN'S HOSPITAL MEDICAL CENTER ,  THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN ,  KUROME THERAPEUTICS, INC.

发明人： Scott Bryan HOYT ,  Craig Joseph THOMAS ,  Chris James FINOCCHIO ,  Daniel T. STARCZYNOWSKI ,  Gregory J. TAWA ,  Gabriel GRACIA MALDONADO ,  Jan Susan ROSEBAUM

IPC分类号： C07D471/04 ,  C07D519/00 ,  A61K45/06

CPC分类号： C07D471/04 ,  C07D519/00 ,  A61K45/06

摘要： Some embodiments of the disclosure include disclosed compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the disclosed compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the disclosed IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.